Biomarkers

Original Article / VOLUME 6, ISSUE 3, SEPTEMBER 2024

A New Biomarker Copeptin in Determining Disease Severity in COVID-19

Pınar Korkmaz and others

Coronavirus disease (COVID-19) remarkably impacted mortality rates and healthcare resources. The causative virus, SARS-CoV-2, is a member of the β family. Pulmonary manifestations of COVID-19 can range from asymptomatic infection to severe pneumonia and acute respiratory distress syndrome. Research regarding risk classifications [...] Read More

Original Article / VOLUME 5, ISSUE 4, DECEMBER 2023

Association of Serum Krebs von den Lungen-6 (KL-6) Levels and Disease Severity in Patients Hospitalized with COVID-19

Oğuz Evlice and others

Acute lung injury and sepsis are among the severe clinical outcomes of the coronavirus disease 2019 (COVID-19). Risk factors raise fatality rates, increase the burden on countries’ healthcare facilities, and significantly increase health expenditures due to prolonged inpatient periods. Several studies have revealed a severe illness course in COVID-19 patients, especially in males, older age, and comorbid (...) Read More